Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2711872 | Journal of Stroke and Cerebrovascular Diseases | 2008 | 6 Pages |
Abstract
For patients with stroke and a perfusion-/diffusion-weighted imaging mismatch treated with intravenous tissue plasminogen activator at 3 to 6 hours, a substantial change in the baseline NIHSS score (â¥10 points) is a potent discriminator of patients who experience early reperfusion from those who do not. In addition, an NIHSS score of less than or equal to 2 appears to be an excellent end point for phase II studies of reperfusion therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Clinical Neurology
Authors
Wataru MD, Scott PhD, Vincent N. MD, PhD, Maarten G. MD, Stephanie BS, Elaine MD, Gregory W. MD, The DEFUSE Investigators The DEFUSE Investigators,